Corvus Pharmaceuticals
Logotype for Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) investor relations material

Corvus Pharmaceuticals Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Corvus Pharmaceuticals Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Pipeline and mechanism

  • Soquelitinib, an oral selective ITK inhibitor, is in a Phase III registrational trial for relapsed/refractory PTCL and a Phase II atopic dermatitis trial; both are enrolling.

  • ITK inhibition blocks Th2 and Th17 signaling while sparing RLK, preserving Th1 activity; the proposed effect is immune rebalancing, including increased active Tregs, rather than broad immune suppression.

  • Reported binding affinity was KD 6.5 for ITK versus 2,700 for RLK; selectivity is intended to limit off-target effects, and clinical safety was described as comparable to placebo.

  • IP protection extends through November 2037, or 2042 with pharmaceutical extensions; HS enrollment began, and an asthma study is planned for early 2027.

Atopic dermatitis findings

  • In a 72-patient Phase I monotherapy study, the higher-dose, 8-week cohort showed EASI-75 of 75% versus 20% on placebo and IGA 0/1 of 33%.

  • Across cohorts, active treatment separated from placebo as early as week 2; responses were also observed among patients with prior systemic therapy and treatment-resistant patients.

  • EASI-75 responses persisted after treatment ended: the first three cohorts remained near 40% at 90 days off treatment, while the higher-dose cohort maintained response at 30 days off treatment.

  • Biomarkers showed reductions in IL-4, IL-5, IL-13 and TARC, plus increased Tregs that remained elevated off treatment; safety was described as favorable and comparable to placebo.

  • SIERRA1 is enrolling 200 adults across four cohorts, testing 200 mg QD, 200 mg BID and 400 mg QD versus placebo; results are planned for Q3 2027.

Other programs and 2027 milestones

  • The Phase III PTCL trial has a futility analysis planned for Q1 2027 and top-line data expected by year-end 2027; the program has orphan drug and fast track designations.

  • A Phase I-B HS proof-of-concept trial is enrolling up to 25 patients for 12 weeks; safety, HiSCR, IHS4 and skin and blood biomarkers will be assessed, with data expected in H1 2027.

  • The asthma trial is planned to start in early Q1 2027 and enroll both T2 and non-T2 patients, with interim assessment by group; Angel plans to initiate a China asthma trial in Q2.

  • Angel Pharmaceuticals, 49%-owned, is running a China AD study: cohort one data are expected in March 2027, and cohort two data in H2 2027; the partner may expand enrollment by 60–90 patients after Phase I-B.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Corvus Pharmaceuticals earnings date

Logotype for Corvus Pharmaceuticals Inc
Q4 202616 Mar, 2027
Corvus Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Corvus Pharmaceuticals earnings date

Logotype for Corvus Pharmaceuticals Inc
Q4 202616 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies for the treatment of cancer and immune-related diseases. The company’s pipeline includes drug candidates that target key immune pathways to enhance the body’s immune response against cancer cells. The company is headquartered in Burlingame, California, and its shares are listed on the NASDAQ.